1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Drug Targets apoC-III To Lower Triglycerides

 
• By Mandy Jackson

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Anatomical model of pancreas on doctor table over background gastroenterologist consulting woman patient
A high dose of olezarsen eliminated risk of acute pancreatitis in FCS • Source: Shutterstock

Ionis Pharmaceuticals, Inc. took another step forward on its path to bringing its first wholly-owned drug to market without a partner on 26 September when it reported positive topline results from the Phase III BALANCE clinical trial of olezarsen in the treatment of familial chylomicronemia syndrome (FCS). The company plans to file for US and EU approvals during the first half of 2024 and, if granted priority review, expects US Food and Drug Administration approval before the end of next year and a launch soon after.

Key Takeaways

  • Ionis will file for US and EU approvals of olezarsen in FCS during the first half of 2024 based on positive results from the Phase III BALANCE study and expects FDA approval, assuming priority review due to a prior fast track designation, before the end of 2024.

The positive BALANCE readout also bodes well for olezarsen in the much larger indication of severe hypertriglyceridemia (SHTG), which encompasses...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

More from R&D

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.